The introduction of the irreversible first-generation BTK inhibitor, ibrutinib, to clinical practice has changed outcomes for patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM) [1,2,3]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.